Spots Global Cancer Trial Database for refractory
Every month we try and update this database with for refractory cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | NCT00445068 | Multiple Myelom... | LBH589 | 18 Years - | Novartis | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | NCT03465891 | Lymphoma | atezolizumab Low- Dose, Loca... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | NCT03218683 | Relapsed or Ref... | AZD5991 AZD5991 + Venet... | 18 Years - 85 Years | AstraZeneca | |
| Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | NCT00903968 | Multiple Myelom... | Plerixafor bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | NCT02985125 | Metastatic Panc... | LEE011 Everolimus | 18 Years - | Georgetown University | |
| Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | NCT02568683 | Non-Hodgkin Lym... | Entospletinib Vincristine | 18 Years - | Gilead Sciences | |
| Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | NCT00116610 | Small Cell Lung... | picoplatin | 18 Years - | Poniard Pharmaceuticals | |
| Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | NCT02974647 | Lymphoma | Ruxolitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | NCT01522469 | Relapsed or Ref... | Crenolanib Besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 | NCT04070768 | Acute Myeloid L... | Gemtuzumab Ozog... Venetoclax | 18 Years - | Big Ten Cancer Research Consortium | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | NCT02235740 | Cancer | Afuresertib Carfilzomib | 18 Years - | Novartis | |
| Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) | NCT01444742 | Leukemia Myeloproliferat... | Clofarabine Cytarabine | 18 Years - | M.D. Anderson Cancer Center | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | NCT05313243 | T-Cell Lymphoma | Brentuximab ved... Pembrolizumab | 18 Years - | Yale University | |
| TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) | NCT04557436 | B Acute Lymphob... | PBLTT52CAR19 | 6 Months - 18 Years | Great Ormond Street Hospital for Children NHS Foundation Trust | |
| PRecISion Medicine for Children With Cancer | NCT03336931 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Molecular profi... | - 21 Years | Sydney Children's Hospitals Network | |
| A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | NCT02860546 | Refractory Meta... | TAS-102 nivolumab | 18 Years - | Taiho Oncology, Inc. | |
| A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR | NCT02687386 | Solid Tumours CNS Tumours | Mitoxantrone pa... | 2 Years - 21 Years | Sydney Children's Hospitals Network | |
| An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | NCT03989336 | Ovarian Cancer | Manganese Chlor... nab-paclitaxel Platinum chemot... Sintilimab | 18 Years - 70 Years | Chinese PLA General Hospital | |
| Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) | NCT03057990 | Myelodysplastic... | Pyrimethamine | 18 Years - | Montefiore Medical Center | |
| Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | NCT00511238 | Multiple Myelom... | carfilzomib carfilzomib | 18 Years - | Amgen | |
| Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | NCT01449344 | Mantle Cell Lym... | Rituximab High dose Ara-C Dexamethasone Bortezomib | 18 Years - | European Mantle Cell Lymphoma Network | |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | NCT04503265 | Advanced Malign... Breast Cancer Ovarian Cancer Homologous Reco... Prostate Cancer Pancreatic Canc... | AMXI-5001:Dose ... AMXI-5001:Dose ... | 18 Years - | AtlasMedx, Incorporated | |
| Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | NCT02045368 | Breast Cancer Brain Cancer Gastrointestina... Genitourinary C... Gynecologic Can... Head and Neck C... Melanoma Thoracic Cancer... | IGF-Methotrexat... | 18 Years - | IGF Oncology, LLC | |
| iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes | NCT03446638 | Myelodysplastic... | FDA-approved dr... FLAG induction 7 + 3 induction Low-dose cytara... Supportive care... Computational b... | 18 Years - 99 Years | University of Florida | |
| Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02429375 | Hodgkin Lymphom... | Mocetinostat Pl... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | NCT02280811 | Vaginal Cancer Cervical Cancer Anal Cancer Penile Cancer Oropharyngeal C... | Fludarabine Cyclophosphamid... E6 TCR Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | NCT03690869 | Relapsed Solid ... Refractory Soli... Relapsed Centra... Refractory Cent... Diffuse Intrins... High Grade Glio... | cemiplimab (mon... cemiplimab (mai... Conventional or... Re-irradiation | - 25 Years | Regeneron Pharmaceuticals | |
| Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00090727 | Solid Malignanc... Non-Hodgkin's L... | AQ4N | 18 Years - | Novacea | |
| Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma | NCT02039895 | Cutaneous T-cel... | HITS | 18 Years - 80 Years | Far Eastern Memorial Hospital | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer | NCT03706573 | HR+ Advanced or... | alpelisib | 18 Years - | Novartis | |
| Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma | NCT04864522 | Multiple Myelom... | SLAMF7 FPBMC | 18 Years - | University of Virginia | |
| To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors | NCT01199224 | Solid Tumors | veliparib veliparib veliparib veliparib | 18 Years - | AbbVie | |
| A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02532192 | Lymphoma | Belinostat Rituximab Cisplatin Cytarabine Dexamethasone Ciprofloxacin Fluconazole | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | NCT01520805 | Acute Myeloid L... Myelodysplastic... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | NCT01121757 | Follicular Lymp... Marginal Zone L... | azacitidine lenalidomide | 18 Years - | Duke University | |
| Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. | NCT04904237 | Refractory Acut... | Aza-Ven-allo-HS... | 16 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | NCT00689000 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CHR-2797 (tosed... | 18 Years - | Chroma Therapeutics | |
| A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 | NCT04590326 | Ovarian Cancer Fallopian Tube ... Primary Periton... Endometrial Can... | REGN5668 Cemiplimab REGN4018 Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer | NCT01661972 | Metastatic Colo... | Capecitabine an... | 18 Years - | Duke University | |
| A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas | NCT03575351 | Lymphoma, Non-H... | Standard of Car... JCAR017 | 18 Years - 75 Years | Celgene | |
| Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer | NCT02539719 | Ovarian Cancer | SC-003 SC-003 in combi... | 18 Years - | Stemcentrx | |
| CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | NCT04034446 | Relapsed or Ref... | CD19-CD22 CAR-T... | 3 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | NCT01419691 | Chronic Lymphoc... Small Lymphocyt... Leukemia, Proly... | auranofin | 18 Years - | University of Kansas Medical Center | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | NCT02417285 | Lymphoma, Large... Lymphoma, Non-H... | Obinutuzumab CC-122 | 18 Years - | Celgene | |
| Phase 1 Study of Oral TP-1454 | NCT04328740 | Advanced Solid ... Anal Cancer | TP-1454 monothe... | 18 Years - | Sumitomo Pharma America, Inc. | |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | NCT04120246 | Anatomic Stage ... HER2 Positive B... Metastatic Brea... Refractory Brea... | Alpha-tocophery... Trastuzumab | 18 Years - | Veana Therapeutics | |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT05137886 | Hodgkin Lymphom... Relapse Refractory Hodg... | PD-1 inhibitor | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | NCT03765541 | Relapsed or Ref... | Dexamethasone Amsacrine Cytarabine Azacitidine | 18 Years - | University Hospital, Toulouse | |
| Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | NCT02245867 | Amyloidosis | Chimeric Fibril... | 21 Years - | Columbia University | |
| Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma | NCT01460901 | Neuroblastoma | GD2 CAR modifie... | 18 Months - 17 Years | Children's Mercy Hospital Kansas City | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE | NCT02686346 | Hodgkin Disease | Brentuximab Ved... Etoposide Carboplatine Ifosfamide | 18 Years - 65 Years | The Lymphoma Academic Research Organisation | |
| Study of AMV564 in Patients With AML | NCT03144245 | Acute Myeloid L... | AMV564 AMV564 in combi... | 18 Years - | Amphivena Therapeutics, Inc. | |
| Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma | NCT02482532 | Melanoma | tvs-CTL Vaccine | 18 Years - 66 Years | University of Kansas Medical Center | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | NCT00439361 | Hodgkin Lymphom... Lymphoma | Bortezomib Carboplatin Etoposide Ifosfamide Mesna | 16 Years - | M.D. Anderson Cancer Center | |
| Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia | NCT00651781 | Acute Myeloid L... | Bortezomib | 18 Years - | PETHEMA Foundation | |
| A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03372057 | Peripheral T-ce... | Duvelisib Duvelisib Duvelisib | 18 Years - | SecuraBio | |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | NCT03029338 | Lymphomas Non-H... Relapse | CD19 CAR T cell... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Anlotinib and Irinotecan for Ewing Sarcoma | NCT03416517 | Ewing's Tumor M... | Anlotinib Irinotecan | 5 Years - 65 Years | Peking University People's Hospital | |
| An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 | NCT01240642 | Metastatic Canc... Metastatic Canc... | ASA404 | 18 Years - | Novartis | |
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | NCT03742245 | Breast Cancer M... Breast Cancer | Olaparib Vorinostat | 18 Years - | The Methodist Hospital Research Institute | |
| Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | NCT05238311 | Multiple Myelom... | Elranatamab | 18 Years - | Pfizer | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | NCT03029338 | Lymphomas Non-H... Relapse | CD19 CAR T cell... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas | NCT03179930 | Lymphoma Relapsed Refractory | Entinostat Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts | NCT03160079 | B-Cell Acute Ly... | blinatumomab pembrolizumab | 18 Years - | University of California, San Diego | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies | NCT02795182 | Lymphoma Leukemia | Zanubrutinib Tislelizumab | 18 Years - | BeiGene | |
| Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies | NCT00081536 | Colorectal Neop... | Aroplatin (Lipo... | 18 Years - | Aronex Pharmaceuticals | |
| Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | NCT01695330 | Multiple Myelom... | Subcutaneous bo... | 18 Years - | Oncotherapeutics | |
| An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma | NCT01969695 | Non-Hodgkin's L... | ABT-199 | 18 Years - 99 Years | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
